Omeros Corp. (OMER)

20.28
0.66 3.40
NASDAQ : Health Technology
Prev Close 19.62
Open 19.82
Day Low/High 19.70 / 20.45
52 Wk Low/High 10.30 / 27.00
Volume 235.24K
Avg Volume 413.10K
Exchange NASDAQ
Shares Outstanding 49.29M
Market Cap 915.77M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
A Trio of Small Biotech Companies Garnering Attention

A Trio of Small Biotech Companies Garnering Attention

The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.

A Closing Comment on a Biotech Mover

As always it was good to sit in for Doug Kass over the past two trading sessions. Equities lost some traction toward the end of the day. The Dow and S&P 500 closed with OK gains while the NASDAQ was down slightly. Biotech was not the place to be tod...

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

2 Small Biotechs That Continue to Look Good

2 Small Biotechs That Continue to Look Good

Several biotech names held up well or even had solid advances during last week's broad market selloff.

2 Small Biotechs That Look Good

2 Small Biotechs That Look Good

Achaogen and Omeros both rose as the Dow was losing 724 points.

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

Portola Shares Lower After Update on Anticoagulant Launch -- Biotech Movers

The South San Francisco, Calif.-based firm said after the market close on Tuesday that the FDA has extended the review period for the company's prior approval supplement for Bevyxxa (betrixaban).

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Housing Stocks Will See Demand Boost

Housing Stocks Will See Demand Boost

The housing market will continue to improve over the next few years due to pent up demand.

Don't Panic About Biotech

Don't Panic About Biotech

Diversification is absolutely critical when investing in this sector.

3 Housing Plays With Solid Earnings

3 Housing Plays With Solid Earnings

These names are building a sound foundation for growth.

These 3 Small Biotechs Have a Healthy Shot

These 3 Small Biotechs Have a Healthy Shot

Several firms hiked price targets on Portola into the $70s this week.

Give These 3 Small Biotechs a Shot

Give These 3 Small Biotechs a Shot

Several firms hiked price targets on Portola into the $70s this week.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

Cruising Through the Grocery and Biotech Aisles

Looks like the grocery sector is going to be a theme for this Friday. In the story of the day, and maybe of the week, Amazon  has announced it will buy organic food pioneer Whole Foods for $42 a share in an all-cash transaction. Walmart is down 5% i...

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

The Dip Buyers Aren't Delivering Much Right Now

The Dip Buyers Aren't Delivering Much Right Now

The indices are holding key support, but this isn't translating into any real momentum.

3 Small Biotechs That Still Have Upside

3 Small Biotechs That Still Have Upside

Companies developing drugs for cancer, eye problems and pets -- offer untapped value.

Oil, Equity Indices Higher

The market has strengthened considerably since our last update, with all the major indices sporting solid gains across the board. Oil is also up 1% on the day. Restaurant stocks are having a good day after solid earnings reports from Yum Brands  and...

Scanning the Biotech Universe

Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...

3 Small-Cap Biotech Names for 2017

In our last post we discussed large-cap biotech names that have been beaten up in 2016, are cheap and hopefully will see better days in 2017. Here are a few small-cap biotechs I would keep an eye on in 2017. The following is a quick rundown. Aratana...

An Uninspired Start

And we are off. The market has opened opens slightly lower across the board. We're seeing some profit taking early on in stocks and sectors that have done extremely well since the election. United Rentals , after massive run over the past week, is d...

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

2 Mistreated Small-Caps to Buy on Pullbacks

2 Mistreated Small-Caps to Buy on Pullbacks

Biotech Omeros and builder LGI Homes both seem substantially undervalued given their prospects.

Main Biotech Indices Surrender Yesterday's Gains

It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...

Opening May Be Flat, but There's Action Aplenty

The market looks like it is going to open pretty flat today based on current pre-market future levels. General Electric will not be a tailwind after the giant industrial concern trimmed its forward revenue forecast due to an anemic global demand pic...

More Picks for a Rough Market

More Picks for a Rough Market

Let's look at other attractively valued bets in what is at least a slightly overbought market overall.

Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

Quant Picks: 3 Pharmaceutical Companies to Sell Right Now

Quant Picks: 3 Pharmaceutical Companies to Sell Right Now

Here are some of the worst companies TheStreet Quant Ratings says you should consider selling.

The Market Caved

But how long will it last?